Table 5 Univariate and multivariate analyses of OS in 78 patients with advanced hepatocellular carcinoma who received low-dose nivolumab
From: Low-dose nivolumab in advanced hepatocellular carcinoma
Characteristics | No. of patients | Univariate | Multivariate | ||
|---|---|---|---|---|---|
OS (months) | P value | HR (95% CI) | P value | ||
Age | |||||
  < 60 years | 29 (37.2%) | 7.6 | 0.26 |  |  |
  ≥ 60 years | 49 (62.8%) | 20.2 |  |  |  |
Sex | |||||
 Male | 61 (78.2%) | 12.3 | 0.82 |  |  |
 Female | 17 (21.8%) | 20.2 |  |  |  |
ECOG PS | |||||
 0 | 34 (43.6%) | 12.3 | 0.36 |  |  |
 1 | 44 (56.4%) | 11.8 |  |  |  |
Child–Pugh classification | |||||
 A | 58 (74.4%) | 20.2 | 0.022* |  |  |
 B (7) | 20 (25.6%) | 5.2 |  |  |  |
ALBI grade | |||||
 1 | 33 (42.3%) | 35.9 | 0.017* | 0.46 (0.24–0.88) | 0.020* |
 2 | 45 (57.7%) | 10.8 |  |  |  |
Hepatitis B | |||||
 Yes | 49 (62.8%) | 10.8 | 0.60 |  |  |
 No | 29 (37.2%) | 20.2 |  |  |  |
Hepatitis C | |||||
 Yes | 23 (29.5%) | 11.8 | 0.95 |  |  |
 No | 55 (70.5%) | 12.3 |  |  |  |
Macrovascular invasion (IVC, HV, PV) | |||||
 Yes | 39 (50%) | 20.2 | 0.88 |  |  |
 No | 39 (50%) | 10.8 |  |  |  |
Main portal vein thrombosis | |||||
 Yes | 11 (14.1%) | 6.1 | 0.09 |  |  |
 No | 67 (85.9%) | 13.8 |  |  |  |
History of hepatectomy | |||||
 Yes | 31 (39.7%) | 38.2 | 0.07 |  |  |
 No | 47 (60.3%) | 10.8 |  |  |  |
Extrahepatic spread | |||||
 Yes | 39 (50%) | 20.2 | 0.50 |  |  |
 No | 39 (50%) | 10.8 |  |  |  |
Lymph node metastasis | |||||
 Yes | 27 (34.6%) | 20.2 | 0.49 |  |  |
 No | 51 (65.4%) | 10.8 |  |  |  |
Nivolumab dose | |||||
 20 mg | 17 (21.8%) | 20.2 | 0.20 |  |  |
 100 mg | 61 (78.2%) | 10.6 |  |  |  |
Treatment lines | |||||
 Second line | 45 (57.7%) | 12.5 | 0.37 |  |  |
 Third line and later lines | 33 (42.3%) | 11.8 |  |  |  |
AFP ≥400 ng/ml | |||||
 Yes | 41 (52.6%) | 10.7 | 0.34 |  |  |
 No | 37 (47.4%) | 21.7 |  |  |  |